Overview
TCRX market data
Price History
TCRX price chart · 1M
- O
- 0.777700
- H
- 0.777900
- L
- 0.747500
- C
- 0.756000
- Vol
- 9,058.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.78
- Previous Close
- $0.78
- Day High
- $0.78
- Day Low
- $0.75
- 52 Week High
- $1.34
- 52 Week Low
- $0.72
- 7 Day Return
- -2.98%
- 30 Day Return
- -1.83%
- 90 Day Return
- -30.32%
- 1 Year Return
- -34.55%
- Daily Notional Volume
- $6.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.14 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,360.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.72 – $2.57 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $50.5M · P/B 0.46 · P/S 5.52.
Company News
12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · Aug 19, 2026, 9:05 PM
Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026Benzinga · Aug 18, 2026, 9:08 PM
8-K filing — TScan Therapeutics, Inc. (TCRX)SEC EDGAR · Aug 18, 2026, 9:00 PM
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price TargetBenzinga · Aug 12, 2026, 3:25 PM
TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M EstimateBenzinga · Aug 12, 2026, 11:10 AM
TScan Therapeutics Announces First Patient Infused With TSC-101 In Pivotal Phase 3 ALLOHA-2 Trial For AML, MDS Relapse Prevention After TransplantBenzinga · Jul 29, 2026, 11:06 AM
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price TargetBenzinga · Jun 23, 2026, 12:25 PM
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price TargetBenzinga · Jun 23, 2026, 11:50 AM
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell TransplantationGlobenewswire Inc · Jun 22, 2026, 11:15 AM
TScan Says Cancer Therapy Data Support Move to Phase 3 TrialBenzinga · Jun 22, 2026, 11:10 AM